Economic evaluations of adjuvant trastuzumab were reviewed. Three primary shortcomings were identified including incorporation of local data and estimation and representation (visual) of decision uncertainty.
Nathalie A. Kulin, MSc
Advertisement
Articles by Nathalie A. Kulin, MSc
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
COVID Is Back in the Bay Area: Is It the XFG "Stratus" Variant?
2
What Comes After Anti-VEGF in Wet AMD: Arshad Khanani, MD
3
Zanubrutinib Outlasting Acalabrutinib in CLL
4
FDA Clears Lerodalcibep-Liga Autoinjector, Widens LDL-C Indication
5